Cardiovascular Outcomes associated with Oral Anticoagulants, Antiplatelets and No-Treatment after Atrial Fibrillation Ablation: A Nationwide Cohort Study A Nationwide Cohort Study

Main Article Content

Deniz Karasoy Gunnar Hilmar Gislason Christian Torp-Pedersen Jonas Bjerring Olesen Matteo Anselmino Patricia Fruelund Jacob Moesgaard Larsen Sam Riahi

Abstract

Objective: We investigated the long-term cardiovascular outcomes associated with direct oral anticoagulants (DOACs), antiplatelets and No-Treatment compared to warfarin beyond 90-days after atrial fibrillation (AF) catheter ablation.


Methods: We identified 12,010 AF patients undergoing first-time ablation in Denmark (2002-2018) and analyzed stroke, serious bleeding, cardiovascular death and the composite of these three endpoints (MACE) by incidence rates (IR) per 1000 person-years and Cox proportional-hazard models.


Results: The median age was 62 years (interquartile range [IQR]: 54-68 years); 28.8% were female, 7225 (60.2%) patients were younger than 65-years, and 6927 (57.7%) patients had CHA2DS2-VASc score≥2. Over a total of 65,990 person-years follow-up commencing 90-days after first-time ablation, warfarin, DOACs, antiplatelets and ‘No-treatment’ exposures covered 30,877 (46.8%), 9,452 (14.3%), 6,003 (9.1%) and 19,657 (29.8%) person-years, respectively. There was no difference between DOACs vs warfarin (HR 1.04 [0.77-1.42]95%CI) while antiplatelets (HR 1.50 [1.11-2.05]95%CI) and No-Treatment (HR 1.50 [1.15-1.94]95%CI) were associated with a significantly higher rate of stroke. DOACs (HR 0.70 [0.54-0.92]95%CI), antiplatelets (HR 0.58 [0.41-0.82]95%CI) and No-Treatment (HR 0.52 [0.39-0.69]95%CI) were associated with a significantly lower rate of serious bleeding compared with warfarin. We found no difference between DOACs and warfarin (HR 0.87 [0.61-1.25]95%CI) while Antiplatelets (HR 1.42 [1.04-1.94]95%CI) and No-treatment (HR 2.77 [2.16-3.56]95%CI) were associated with a significantly higher rate of cardiovascular death. We observed no difference with DOACs (HR 0.86 [0.70-1.05]95%CI), antiplatelets (HR 1.04 [0.84-1.27]95%CI) or No-Treatment (HR 1.10 [0.93-1.31]]95%CI) compared to warfarin in multivariable analyses regarding the composite endpoint of MACE.


Conclusions: Our study indicates a better bleeding risk profile associated with DOACs than warfarin in patients undergoing AF ablation, but no difference for the endpoints of stroke, cardiovascular death, or the composite endpoint of MACE. Despite the favourable bleeding risk, antiplatelets and No-Treatment compared with warfarin appear hazardous due to a higher rate of stroke and cardiovascular death.

Article Details

How to Cite
KARASOY, Deniz et al. Cardiovascular Outcomes associated with Oral Anticoagulants, Antiplatelets and No-Treatment after Atrial Fibrillation Ablation: A Nationwide Cohort Study. Medical Research Archives, [S.l.], v. 10, n. 6, june 2022. ISSN 2375-1924. Available at: <https://esmed.org/MRA/mra/article/view/2837>. Date accessed: 16 apr. 2024. doi: https://doi.org/10.18103/mra.v10i6.2837.
Section
Research Articles

References

1. Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2020;(ehaa612):doi: 10.1093/eurheartj/ehaa612. doi:10.1093/eurheartj/ehaa612
2. Calkins H, Hindricks G, Cappato R, et al. 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation: Executive summary. Europace. 2018;20(1):157-208. doi:10.1093/europace/eux275
3. Packer DL, Mark DB, Robb RA, et al. Catheter Ablation versus Antiarrhythmic Drug Therapy for Atrial Fibrillation (CABANA) Trial: Study Rationale and Design. Am Heart J. 2018;199:192-199. doi:10.1016/j.ahj.2018.02.015
4. Saglietto A, De Ponti R, Di Biase L, et al. Impact of atrial fibrillation catheter ablation on mortality, stroke, and heart failure hospitalizations: A meta-analysis. J Cardiovasc Electrophysiol. 2020;31(5):1040-1047. doi:10.1111/jce.14429
5. Khan SU, Rahman H, Talluri S, Kaluski E. The Clinical Benefits and Mortality Reduction Associated With Catheter Ablation in Subjects With Atrial Fibrillation: A Systematic Review and Meta-Analysis. JACC Clin Electrophysiol. 2018;4(5):626-635. doi:10.1016/j.jacep.2018.03.003
6. Chen C, Zhou X, Zhu M, et al. Catheter ablation versus medical therapy for patients with persistent atrial fibrillation: a systematic review and meta-analysis of evidence from randomized controlled trials. J Interv Card Electrophysiol. 2018;52(1):9-18. doi:10.1007/s10840-018-0349-8
7. Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet (London, England). 2014;383(9921):955-962. doi:10.1016/S0140-6736(13)62343-0
8. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139-1151. doi:10.1056/NEJMoa0905561
9. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883-891. doi:10.1056/NEJMoa1009638
10. Granger CB, Alexander JH, McMurray JJ V, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981-992. doi:10.1056/NEJMoa1107039
11. Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369(22):2093-2104. doi:10.1056/NEJMoa1310907
12. Karasoy D, Gislason GH, Hansen J, et al. Temporal changes in patient characteristics and prior pharmacotherapy in patients undergoing radiofrequency ablation of atrial fibrillation: A Danish nationwide cohort study. Europace. 2013;15(5):669-675. doi:10.1093/europace/eus418
13. Bendix Carstensen. Lexis: a SAS-macro for splitting follow-up time. http://www.bendixcarstensen.com/Lexis/Lexis.sas. Published 2011. Accessed May 3, 2021.
14. Krarup L-H, Boysen G, Janjua H, Prescott E, Truelsen T. Validity of stroke diagnoses in a National Register of Patients. Neuroepidemiology. 2007;28(3):150-154. doi:10.1159/000102143
15. Cunningham A, Stein CM, Chung CP, Daugherty JR, Smalley WE, Ray WA. An automated database case definition for serious bleeding related to oral anticoagulant use. Pharmacoepidemiol Drug Saf. 2011;20(6):560-566. doi:10.1002/pds.2109
16. Karasoy D, Gislason GH, Hansen J, et al. Oral anticoagulation therapy after radiofrequency ablation of atrial fibrillation and the risk of thromboembolism and serious bleeding: Long-term follow-up in nationwide cohort of Denmark. Eur Heart J. 2015;36(5):307-314a. doi:10.1093/eurheartj/ehu421
17. Gerds T a, Scheike TH, Andersen PK. Absolute risk regression for competing risks: interpretation, link functions, and prediction. Stat Med. 2012;31(29):3921-3930. doi:10.1002/sim.5459
18. Richardson DB, Kinlaw AC, MacLehose RF, Cole SR. Standardized binomial models for risk or prevalence ratios and differences. Int J Epidemiol. 2015;44(5):1660-1672. doi:10.1093/ije/dyv137
19. Tran VN, Tessitore E, Gentil-Baron P, et al. Thromboembolic events 7-11 years after catheter ablation of atrial fibrillation. PACE-Pacing Clin Electrophysiol. 2015;38(4):499-506. doi:10.1111/pace.12588
20. Själander S, Holmqvist F, Smith JG, et al. Assessment of use vs discontinuation of oral anticoagulation after pulmonary vein isolation in patients with atrial fibrillation. JAMA Cardiol. 2017;2(2):146-152. doi:10.1001/jamacardio.2016.4179
21. Nührich JM, Kuck KH, Andresen D, et al. Oral anticoagulation is frequently discontinued after ablation of paroxysmal atrial fibrillation despite previous stroke: data from the German Ablation Registry. Clin Res Cardiol. 2015;104(6):463-470. doi:10.1007/s00392-014-0804-1
22. Atti V, Turagam MK, Viles-Gonzalez JF, Lakkireddy D. Anticoagulation After Catheter Ablation of Atrial Fibrillation: Is it time to Discontinue in Select Patient Population? J Atr Fibrillation. 2018;11(4):2092. doi:10.4022/jafib.2092
23. Proietti R, AlTurki A, Di Biase L, et al. Anticoagulation after catheter ablation of atrial fibrillation: An unnecessary evil? A systematic review and meta-analysis. J Cardiovasc Electrophysiol. 2019;30(4):468-478. doi:10.1111/jce.13822
24. Liu X-H, Xu Q, Luo T, Zhang L, Liu H-J. Discontinuation of oral anticoagulation therapy after successful atrial fibrillation ablation: A systematic review and meta-analysis of prospective studies. PLoS One. 2021;16(6):e0253709. doi:10.1371/journal.pone.0253709
25. Romero J, Cerrud-Rodriguez RC, Diaz JC, et al. Oral anticoagulation after catheter ablation of atrial fibrillation and the associated risk of thromboembolic events and intracranial hemorrhage: A systematic review and meta-analysis. J Cardiovasc Electrophysiol. 2019;30(8):1250-1257. doi:10.1111/jce.14052